{"id":344546,"date":"2025-08-24T08:30:07","date_gmt":"2025-08-24T08:30:07","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/how-to-buy-mannkind-corporation\/"},"modified":"2025-08-24T08:30:07","modified_gmt":"2025-08-24T08:30:07","slug":"how-to-buy-mannkind-corporation","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-mannkind-corporation\/","title":{"rendered":"MannKind Corporation (MNKD) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; MannKind Corporation (MNKD) Hisse Senedi Yat\u0131r\u0131m\u0131"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334045,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-344546","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"MannKind Corporation (MNKD) Hisseleri Nas\u0131l Al\u0131n\u0131r - MannKind Corporation (MNKD) Hisse Senedi Yat\u0131r\u0131m\u0131","h1_source":{"label":"H1","type":"text","formatted_value":"MannKind Corporation (MNKD) Hisseleri Nas\u0131l Al\u0131n\u0131r - MannKind Corporation (MNKD) Hisse Senedi Yat\u0131r\u0131m\u0131"},"description":"MannKind Corporation (MNKD) hisselerinin nas\u0131l al\u0131naca\u011f\u0131n\u0131 \u00f6\u011frenin, 2025 i\u00e7in bu yenilik\u00e7i biyoteknoloji \u015firketinin g\u00fcncel fiyat trendlerini, risklerini ve b\u00fcy\u00fcme f\u0131rsatlar\u0131n\u0131 anlay\u0131n.","description_source":{"label":"Description","type":"textarea","formatted_value":"MannKind Corporation (MNKD) hisselerinin nas\u0131l al\u0131naca\u011f\u0131n\u0131 \u00f6\u011frenin, 2025 i\u00e7in bu yenilik\u00e7i biyoteknoloji \u015firketinin g\u00fcncel fiyat trendlerini, risklerini ve b\u00fcy\u00fcme f\u0131rsatlar\u0131n\u0131 anlay\u0131n."},"intro":"Diyabet tedavisinde devrim yaratan bir \u015firkete yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? MannKind Corporation (MNKD), inhalasyon yoluyla uygulanan terap\u00f6tiklerin gelece\u011fine ait benzersiz bir f\u0131rsat sunuyor. \u00c7\u0131\u011f\u0131r a\u00e7an Afrezza ins\u00fclinleri ve geni\u015fleyen nadir akci\u011fer hastal\u0131klar\u0131 tedavi hatt\u0131yla, bu biyoteknoloji yenilik\u00e7isi b\u00fcy\u00fcme i\u00e7in biletiniz olabilir. MNKD hisselerine yat\u0131r\u0131m yaparken bilmeniz gereken her \u015feyi birlikte inceleyelim.","intro_source":{"label":"Intro","type":"text","formatted_value":"Diyabet tedavisinde devrim yaratan bir \u015firkete yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? MannKind Corporation (MNKD), inhalasyon yoluyla uygulanan terap\u00f6tiklerin gelece\u011fine ait benzersiz bir f\u0131rsat sunuyor. \u00c7\u0131\u011f\u0131r a\u00e7an Afrezza ins\u00fclinleri ve geni\u015fleyen nadir akci\u011fer hastal\u0131klar\u0131 tedavi hatt\u0131yla, bu biyoteknoloji yenilik\u00e7isi b\u00fcy\u00fcme i\u00e7in biletiniz olabilir. MNKD hisselerine yat\u0131r\u0131m yaparken bilmeniz gereken her \u015feyi birlikte inceleyelim."},"body_html":"<h2>\ud83d\udcc8 MannKind Hissesi: G\u00fcncel Fiyat ve Piyasa Konumu<\/h2> <p>24 A\u011fustos 2025 itibar\u0131yla MannKind Corporation (MNKD), NASDAQ borsas\u0131nda <strong>4,11 $<\/strong> seviyesinden i\u015flem g\u00f6r\u00fcyor. \u015eirket, 2025 ikinci \u00e7eyrek gelirlerinde 76,5 milyon $ ile etkileyici bir dayan\u0131kl\u0131l\u0131k g\u00f6sterdi ve y\u0131ll\u0131k %6 art\u0131\u015f kaydetti (<a href=\"https:\/\/www.globenewswire.com\/news-release\/2025\/08\/06\/3128213\/0\/en\/MannKind-Corporation-Reports-Second-Quarter-2025-Financial-Results-And-Provides-Business-Update.html\">2025 2. \u00c7eyrek Kazan\u00e7 Raporu<\/a>).<\/p> <h3>Takviminize Not Edin: 6 Kas\u0131m 2025<\/h3> <p>Bu tarih MNKD yat\u0131r\u0131mc\u0131lar\u0131 i\u00e7in son derece kritik. \u015eirket, 2025 \u00fc\u00e7\u00fcnc\u00fc \u00e7eyrek kazan\u00e7 raporunu bu tarihte a\u00e7\u0131klayacak. Tarihsel olarak, MannKind\u2019in kazan\u00e7 duyurular\u0131 \u00f6nemli fiyat hareketlerine neden olmu\u015ftur.<\/p> [cta_green text=\"Ticarete Ba\u015fla\"]<h3>Kazan\u00e7 Raporlar\u0131 MNKD Hissesini Nas\u0131l Hareket Ettirir<\/h3> <table> <thead> <tr><th>Tarih<\/th><th>Olay<\/th><th>Haber \u00d6ncesi Fiyat<\/th><th>Haber Sonras\u0131 De\u011fi\u015fim<\/th><\/tr> <\/thead> <tbody> <tr><td>6 A\u011fu 2025<\/td><td>2. \u00c7eyrek Kazan\u00e7lar\u0131<\/td><td>3,95 $<\/td><td>%4,1 Art\u0131\u015f (EPS tahminlerini a\u015ft\u0131)<\/td><\/tr> <tr><td>May\u0131s 2025<\/td><td>FDA Ba\u015fvurusu<\/td><td>4,20 $<\/td><td>%8,7 Art\u0131\u015f (pediatrik Afrezza)<\/td><\/tr> <tr><td>\u015eub 2025<\/td><td>4. \u00c7eyrek Sonu\u00e7lar\u0131<\/td><td>3,80 $<\/td><td>%6,3 Art\u0131\u015f (gelir b\u00fcy\u00fcmesi)<\/td><\/tr> <tr><td>Kas 2024<\/td><td>Ortakl\u0131k Haberi<\/td><td>4,50 $<\/td><td>%3,2 D\u00fc\u015f\u00fc\u015f (piyasa belirsizli\u011fi)<\/td><\/tr> <tr><td>A\u011fu 2024<\/td><td>2. \u00c7eyrek Sonu\u00e7lar\u0131<\/td><td>4,10 $<\/td><td>%5,1 Art\u0131\u015f (royalty b\u00fcy\u00fcmesi)<\/td><\/tr> <\/tbody> <\/table> <p><strong>Trend \u0130\u00e7g\u00f6r\u00fcs\u00fc<\/strong>: Pozitif kazan\u00e7 s\u00fcrprizleri genellikle MNKD\u2019yi %4-9 aras\u0131nda art\u0131r\u0131rken, d\u00fczenleyici d\u00f6n\u00fcm noktalar\u0131 daha b\u00fcy\u00fck hareketlere yol a\u00e7abilir. Son desen, yat\u0131r\u0131mc\u0131lar\u0131n uygulamadaki g\u00fcveninin artt\u0131\u011f\u0131n\u0131 g\u00f6steriyor.<\/p> <h3>\ud83d\udcca 6 Ayl\u0131k Fiyat Yolculu\u011fu (\u015eubat-A\u011fustos 2025)<\/h3> <p>MannKind hisseleri \u00f6nemli volatilite ya\u015fad\u0131 ancak umut verici toparlanma i\u015faretleri g\u00f6steriyor:<\/p> <ul> <li><strong>\u015eubat<\/strong>: 3,80 $ (tatil sonras\u0131 konsolidasyon)<\/li> <li><strong>Mart<\/strong>: 4,50 $ (FDA ba\u015fvurusu heyecan\u0131)<\/li> <li><strong>Nisan<\/strong>: 4,20 $ (kar realizasyonu d\u00f6nemi)<\/li> <li><strong>May\u0131s<\/strong>: 3,95 $ (genel biyoteknoloji piyasa d\u00fczeltmesi)<\/li> <li><strong>Haziran<\/strong>: 3,70 $ (yaz durgunlu\u011fu)<\/li> <li><strong>Temmuz<\/strong>: 4,00 $ (erken toparlanma i\u015faretleri)<\/li> <li><strong>A\u011fustos<\/strong>: 4,11 $ (mevcut momentum art\u0131\u015f\u0131)<\/li> <\/ul> <p><strong>Son g\u00fc\u00e7lenmenin nedeni nedir?<\/strong><\/p> <ul> <li>G\u00fc\u00e7l\u00fc 2. \u00e7eyrek gelir b\u00fcy\u00fcmesi %6 Y\u0131ll\u0131k<\/li> <li>United Therapeutics ortakl\u0131\u011f\u0131ndan rekor Tyvaso DPI royalty \u00f6demeleri<\/li> <li>NTM Faz 3 denemesinde planlanandan \u00f6nce g\u00fc\u00e7l\u00fc hasta kayd\u0131<\/li> <li>Pediatrik Afrezza sBLA ba\u015fvurusu yeni pazar potansiyeli yarat\u0131yor<\/li> <\/ul> <h3>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h3> <ul> <li><strong>2025 (Y\u0131l Sonu)<\/strong>: 6,50-7,00 $ aral\u0131\u011f\u0131<br\/>Analist konsens\u00fcs\u00fc ve \u00fcr\u00fcn hatt\u0131 kataliz\u00f6rlerine dayanarak, pediatrik onay gelirse ve NTM deneme verileri olumlu olursa MNKD bu aral\u0131\u011f\u0131n \u00fcst s\u0131n\u0131r\u0131na ula\u015fabilir (<a href=\"https:\/\/stockanalysis.com\/stocks\/mnkd\/forecast\/\">Analist Hedefleri<\/a>).<\/li> <li><strong>2026 Tahmini<\/strong>: 6,75-7,25 $<br\/>Afrezza endikasyonlar\u0131n\u0131n geni\u015flemesi ve MNKD-201 Faz 2 ba\u015flat\u0131lmas\u0131 muhtemel b\u00fcy\u00fcmeyi destekleyecektir.<\/li> <li><strong>2028 Projeksiyonu<\/strong>: 7,25-7,75 $<br\/>2028\u2019e kadar MNKD-101 ticarile\u015fmesi ve uluslararas\u0131 varl\u0131\u011f\u0131n geni\u015flemesi s\u00fcrd\u00fcr\u00fclebilir b\u00fcy\u00fcmeyi tetikleyecektir.<\/li> <li><strong>2030 Uzun Vadeli Hedef<\/strong>: 7,77 $<br\/>Analistler, mevcut b\u00fcy\u00fcme e\u011filimi ve piyasa geni\u015flemesine dayanarak MNKD\u2019nin bu seviyeye ula\u015fabilece\u011fini \u00f6ng\u00f6r\u00fcyor (<a href=\"https:\/\/stockscan.io\/stocks\/MNKD\/forecast\">Uzun Vadeli Tahmin<\/a>).<\/li> <\/ul> <p><strong>Sonu\u00e7<\/strong>: Uzun vadeli yat\u0131r\u0131mc\u0131lar i\u00e7in <strong>AL<\/strong>. Mevcut fiyat, \u00f6n\u00fcm\u00fczdeki bir\u00e7ok kataliz\u00f6rle cazip bir giri\u015f noktas\u0131 sunuyor.<\/p> <h3>\u26a0\ufe0f Temel Riskler ve Pozitif \u0130\u015faretler<\/h3> <h4>Dikkate Al\u0131nmas\u0131 Gereken Riskler<\/h4> <ul> <li><strong>FDA Onay Belirsizli\u011fi<\/strong>: Gecikmeler veya reddedilmeler b\u00fcy\u00fcme yolunu \u00f6nemli \u00f6l\u00e7\u00fcde etkileyebilir<\/li> <li><strong>Tedarik Zinciri K\u0131r\u0131lganl\u0131klar\u0131<\/strong>: K\u00fcresel ticaret politikalar\u0131 operasyonel maliyetleri art\u0131rabilir (<a href=\"https:\/\/www.ainvest.com\/news\/mannkind-corporation-faces-global-supply-chain-risks-due-international-trade-policies-2508\/\">Tedarik Zinciri Riskleri<\/a>)<\/li> <li><strong>Mali Volatilite<\/strong>: Son bilan\u00e7o, y\u00fck\u00fcml\u00fcl\u00fcklerin cari varl\u0131klar\u0131 ge\u00e7ti\u011fini g\u00f6steriyor<\/li> <li><strong>Rekabet Bask\u0131s\u0131<\/strong>: Novo Nordisk ve Eli Lilly gibi b\u00fcy\u00fck oyuncular diyabet alan\u0131nda hakim<\/li> <\/ul> <h4>2025-2026 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar<\/h4> <ul> <li><strong>G\u00fc\u00e7l\u00fc Gelir B\u00fcy\u00fcmesi<\/strong>: 2025 2. \u00e7eyrekte %6 Y\u0131ll\u0131k art\u0131\u015f, y\u0131lba\u015f\u0131ndan itibaren %12 y\u00fckseli\u015f<\/li> <li><strong>\u00dcr\u00fcn Hatt\u0131 \u0130lerlemesi<\/strong>: NTM Faz 3 denemesinde planlanandan \u00f6nce hasta kayd\u0131<\/li> <li><strong>Analist G\u00fcveni<\/strong>: 6 Wall Street analisti \"Al\" notunu koruyor, ortalama hedef fiyat 9,17 $ (+%123 potansiyel)<\/li> <li><strong>Stratejik Ortakl\u0131klar<\/strong>: United Therapeutics i\u015fbirli\u011fi rekor royalty gelirleri sa\u011fl\u0131yor<\/li> <li><strong>Pazar Geni\u015flemesi<\/strong>: Pediatrik Afrezza ba\u015fvurusu 500M$+ yeni pazar f\u0131rsat\u0131 a\u00e7\u0131yor<\/li> <\/ul> <h3>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h3> <ol> <li><strong>K\u00fc\u00e7\u00fck Ba\u015flay\u0131n<\/strong>: Toplam portf\u00f6y\u00fcn\u00fcz\u00fcn %3-5\u2019inden fazlas\u0131n\u0131 temsil etmeyen bir pozisyon b\u00fcy\u00fckl\u00fc\u011f\u00fc ile ba\u015flay\u0131n<\/li> <li><strong>Dolar Maliyet Ortalamas\u0131 Kullan\u0131n<\/strong>: M\u00fckemmel giri\u015f zaman\u0131n\u0131 beklemek yerine ayl\u0131k sabit tutarlarda yat\u0131r\u0131m yap\u0131n<\/li> <li><strong>Fiyat Uyar\u0131lar\u0131 Kurun<\/strong>: 6 Kas\u0131m kazan\u00e7 tarihi civar\u0131nda potansiyel al\u0131m f\u0131rsatlar\u0131n\u0131 izleyin<\/li> <li><strong>\u00c7e\u015fitlendirin<\/strong>: Biyoteknoloji tahsisinizi asla tek bir hisseye koymay\u0131n<\/li> <\/ol> <p><strong>Deneyimli bir t\u00fcccardan esprili yorum<\/strong>: \"MNKD ticareti, inhalasyon yoluyla ins\u00fclin kullanmak gibidir - en iyi sonu\u00e7lar i\u00e7in m\u00fckemmel zamanlama gerekir, ama bazen s\u00fcrece g\u00fcvenip o tatl\u0131 emilimi beklemek zorundas\u0131n\u0131z!\"<\/p> <h3>\u2705 MannKind Corporation (MNKD) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ad\u0131m Ad\u0131m<\/h3> <table> <thead> <tr><th>Ad\u0131m<\/th><th>\u0130\u015flem<\/th><th>Neden \u00d6nemli<\/th><\/tr> <\/thead> <tbody> <tr><td>1<\/td><td>Bir Ticaret Platformu Se\u00e7in<\/td><td>NASDAQ listeli hisseleri ve makul komisyon \u00fccretlerini sunmas\u0131na dikkat edin<\/td><\/tr> <tr><td>2<\/td><td>Hesab\u0131n\u0131z\u0131 A\u00e7\u0131n ve Fonlay\u0131n<\/td><td>Risk almaya haz\u0131r oldu\u011funuz bir miktarla ba\u015flay\u0131n - 100 $ bile ba\u015flang\u0131\u00e7 i\u00e7in yeterlidir<\/td><\/tr> <tr><td>3<\/td><td>\"MNKD\" Aramas\u0131 Yap\u0131n<\/td><td>\u015eirket ad\u0131 yerine borsa sembol\u00fcn\u00fc kullan\u0131n<\/td><\/tr> <tr><td>4<\/td><td>Emir T\u00fcr\u00fcn\u00fc Se\u00e7in<\/td><td>Piyasa emirleri yerine limit emirleri kullanarak giri\u015f fiyat\u0131n\u0131z\u0131 kontrol edin<\/td><\/tr> <tr><td>5<\/td><td>\u0130nceleyin ve Onaylay\u0131n<\/td><td>Emir detaylar\u0131n\u0131 iki kez kontrol edin ve i\u015flem \u00f6ncesi \u00fccretleri anlay\u0131n<\/td><\/tr> <tr><td>6<\/td><td>Pozisyonunuzu \u0130zleyin<\/td><td>Kazan\u00e7 tarihleri ve \u00f6nemli haberler i\u00e7in uyar\u0131lar kurun<\/td><\/tr> <tr><td>7<\/td><td>Vergi Etkilerini D\u00fc\u015f\u00fcn\u00fcn<\/td><td>Avantajl\u0131 vergi muamelesi i\u00e7in tutma s\u00fcresi gereksinimlerini anlay\u0131n<\/td><\/tr> <tr><td>8<\/td><td>\u00c7\u0131k\u0131\u015f Stratejinizi Planlay\u0131n<\/td><td>K\u00e2r hedeflerinizi ve zarar durdurma seviyelerinizi \u00f6nceden belirleyin<\/td><\/tr> <\/tbody> <\/table> <h3>\ud83d\udca1 Neden Pocket Option Yeni MNKD Yat\u0131r\u0131mc\u0131lar\u0131 \u0130\u00e7in Uygun?<\/h3> <p>MannKind ile yat\u0131r\u0131m yolculu\u011funa ba\u015flamak isteyenler i\u00e7in Pocket Option birka\u00e7 avantaj sunar:<\/p> <ul> <li><strong>Minimum Para Yat\u0131rma<\/strong>: Sadece 5 $ ile pozisyonunuzu kademeli olarak olu\u015fturmaya ba\u015flayabilirsiniz<\/li> <li><strong>H\u0131zl\u0131 Do\u011frulama<\/strong>: Tek bir belge ile KYC i\u015flemini dakikalar i\u00e7inde tamamlay\u0131n<\/li> <li><strong>Esnek Para \u00c7ekme<\/strong>: Karlar\u0131n\u0131za y\u00fczlerce \u00f6deme y\u00f6ntemiyle eri\u015fin<\/li> <li><strong>E\u011fitim Kaynaklar\u0131<\/strong>: Biyoteknoloji yat\u0131r\u0131m\u0131 hakk\u0131nda kapsaml\u0131 <a href=\"\/blog\">Pocket Option blog<\/a> ile \u00f6\u011frenin<\/li> <\/ul> <p>Platformun d\u00fc\u015f\u00fck giri\u015f engeli, MannKind hissesiyle stratejileri test etmek i\u00e7in idealdir ve daha b\u00fcy\u00fck yat\u0131r\u0131mlar yapmadan \u00f6nce deneme imkan\u0131 sunar.<\/p> <h3>\ud83c\udf0d MannKind 2025\u2019te: \u0130nhalasyon Yoluyla Terap\u00f6tiklerde Devrim<\/h3> <p>MannKind Corporation, inhalasyon terap\u00f6tiklerinde yenili\u011fin \u00f6nc\u00fcs\u00fcd\u00fcr. \u00d6zel Technosphere teknolojileri, kuru toz form\u00fclasyonlar\u0131yla derin akci\u011fere h\u0131zl\u0131 emilim sa\u011flar. Bayrak gemisi Afrezza ins\u00fclinlerinin \u00f6tesinde, milyonlarca ki\u015fiyi etkileyen nadir akci\u011fer hastal\u0131klar\u0131 i\u00e7in tedaviler geli\u015ftiriyorlar.<\/p> <p>\u015eirketin mevcut piyasa de\u011feri 1,26 milyar $ olup, rekabet\u00e7i biyofarmas\u00f6tik pazarda b\u00fcy\u00fcyen varl\u0131klar\u0131n\u0131 yans\u0131t\u0131yor (<a href=\"https:\/\/stockanalysis.com\/stocks\/mnkd\/\">Piyasa Verileri<\/a>). Son 12 ayl\u0131k gelirleri 301,74 milyon $ ve net geliri 32,80 milyon $ olan \u015firket, yenilik\u00e7i terapileri k\u00e2rl\u0131 \u015fekilde ticarile\u015ftirme yetene\u011fini g\u00f6stermi\u015ftir.<\/p> <p><strong>2025 i\u00e7in \u0130lgin\u00e7 Bir Ger\u00e7ek<\/strong>: MannKind\u2019in NTM Faz 3 denemesi (ICoN-1), planlanandan \u00f6nce g\u00fc\u00e7l\u00fc hasta kayd\u0131 ile akci\u011fer hastal\u0131klar\u0131 tarihindeki en h\u0131zl\u0131 hasta toplayan denemelerden biri oldu. Bu beklenmedik h\u0131zlanma, sekt\u00f6r analistlerini \u015fa\u015f\u0131rtt\u0131 ve inhalasyon yoluyla uygulanan klofazimin tedavisine hekimlerin g\u00fc\u00e7l\u00fc ilgisini g\u00f6sterdi.<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 MannKind Hissesi: G\u00fcncel Fiyat ve Piyasa Konumu<\/h2>\n<p>24 A\u011fustos 2025 itibar\u0131yla MannKind Corporation (MNKD), NASDAQ borsas\u0131nda <strong>4,11 $<\/strong> seviyesinden i\u015flem g\u00f6r\u00fcyor. \u015eirket, 2025 ikinci \u00e7eyrek gelirlerinde 76,5 milyon $ ile etkileyici bir dayan\u0131kl\u0131l\u0131k g\u00f6sterdi ve y\u0131ll\u0131k %6 art\u0131\u015f kaydetti (<a href=\"https:\/\/www.globenewswire.com\/news-release\/2025\/08\/06\/3128213\/0\/en\/MannKind-Corporation-Reports-Second-Quarter-2025-Financial-Results-And-Provides-Business-Update.html\">2025 2. \u00c7eyrek Kazan\u00e7 Raporu<\/a>).<\/p>\n<h3>Takviminize Not Edin: 6 Kas\u0131m 2025<\/h3>\n<p>Bu tarih MNKD yat\u0131r\u0131mc\u0131lar\u0131 i\u00e7in son derece kritik. \u015eirket, 2025 \u00fc\u00e7\u00fcnc\u00fc \u00e7eyrek kazan\u00e7 raporunu bu tarihte a\u00e7\u0131klayacak. Tarihsel olarak, MannKind\u2019in kazan\u00e7 duyurular\u0131 \u00f6nemli fiyat hareketlerine neden olmu\u015ftur.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/tr\/register\/\" class=\"po-cta-green\">Ticarete Ba\u015fla\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h3>Kazan\u00e7 Raporlar\u0131 MNKD Hissesini Nas\u0131l Hareket Ettirir<\/h3>\n<table>\n<thead>\n<tr>\n<th>Tarih<\/th>\n<th>Olay<\/th>\n<th>Haber \u00d6ncesi Fiyat<\/th>\n<th>Haber Sonras\u0131 De\u011fi\u015fim<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>6 A\u011fu 2025<\/td>\n<td>2. \u00c7eyrek Kazan\u00e7lar\u0131<\/td>\n<td>3,95 $<\/td>\n<td>%4,1 Art\u0131\u015f (EPS tahminlerini a\u015ft\u0131)<\/td>\n<\/tr>\n<tr>\n<td>May\u0131s 2025<\/td>\n<td>FDA Ba\u015fvurusu<\/td>\n<td>4,20 $<\/td>\n<td>%8,7 Art\u0131\u015f (pediatrik Afrezza)<\/td>\n<\/tr>\n<tr>\n<td>\u015eub 2025<\/td>\n<td>4. \u00c7eyrek Sonu\u00e7lar\u0131<\/td>\n<td>3,80 $<\/td>\n<td>%6,3 Art\u0131\u015f (gelir b\u00fcy\u00fcmesi)<\/td>\n<\/tr>\n<tr>\n<td>Kas 2024<\/td>\n<td>Ortakl\u0131k Haberi<\/td>\n<td>4,50 $<\/td>\n<td>%3,2 D\u00fc\u015f\u00fc\u015f (piyasa belirsizli\u011fi)<\/td>\n<\/tr>\n<tr>\n<td>A\u011fu 2024<\/td>\n<td>2. \u00c7eyrek Sonu\u00e7lar\u0131<\/td>\n<td>4,10 $<\/td>\n<td>%5,1 Art\u0131\u015f (royalty b\u00fcy\u00fcmesi)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><strong>Trend \u0130\u00e7g\u00f6r\u00fcs\u00fc<\/strong>: Pozitif kazan\u00e7 s\u00fcrprizleri genellikle MNKD\u2019yi %4-9 aras\u0131nda art\u0131r\u0131rken, d\u00fczenleyici d\u00f6n\u00fcm noktalar\u0131 daha b\u00fcy\u00fck hareketlere yol a\u00e7abilir. Son desen, yat\u0131r\u0131mc\u0131lar\u0131n uygulamadaki g\u00fcveninin artt\u0131\u011f\u0131n\u0131 g\u00f6steriyor.<\/p>\n<h3>\ud83d\udcca 6 Ayl\u0131k Fiyat Yolculu\u011fu (\u015eubat-A\u011fustos 2025)<\/h3>\n<p>MannKind hisseleri \u00f6nemli volatilite ya\u015fad\u0131 ancak umut verici toparlanma i\u015faretleri g\u00f6steriyor:<\/p>\n<ul>\n<li><strong>\u015eubat<\/strong>: 3,80 $ (tatil sonras\u0131 konsolidasyon)<\/li>\n<li><strong>Mart<\/strong>: 4,50 $ (FDA ba\u015fvurusu heyecan\u0131)<\/li>\n<li><strong>Nisan<\/strong>: 4,20 $ (kar realizasyonu d\u00f6nemi)<\/li>\n<li><strong>May\u0131s<\/strong>: 3,95 $ (genel biyoteknoloji piyasa d\u00fczeltmesi)<\/li>\n<li><strong>Haziran<\/strong>: 3,70 $ (yaz durgunlu\u011fu)<\/li>\n<li><strong>Temmuz<\/strong>: 4,00 $ (erken toparlanma i\u015faretleri)<\/li>\n<li><strong>A\u011fustos<\/strong>: 4,11 $ (mevcut momentum art\u0131\u015f\u0131)<\/li>\n<\/ul>\n<p><strong>Son g\u00fc\u00e7lenmenin nedeni nedir?<\/strong><\/p>\n<ul>\n<li>G\u00fc\u00e7l\u00fc 2. \u00e7eyrek gelir b\u00fcy\u00fcmesi %6 Y\u0131ll\u0131k<\/li>\n<li>United Therapeutics ortakl\u0131\u011f\u0131ndan rekor Tyvaso DPI royalty \u00f6demeleri<\/li>\n<li>NTM Faz 3 denemesinde planlanandan \u00f6nce g\u00fc\u00e7l\u00fc hasta kayd\u0131<\/li>\n<li>Pediatrik Afrezza sBLA ba\u015fvurusu yeni pazar potansiyeli yarat\u0131yor<\/li>\n<\/ul>\n<h3>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h3>\n<ul>\n<li><strong>2025 (Y\u0131l Sonu)<\/strong>: 6,50-7,00 $ aral\u0131\u011f\u0131<br \/>Analist konsens\u00fcs\u00fc ve \u00fcr\u00fcn hatt\u0131 kataliz\u00f6rlerine dayanarak, pediatrik onay gelirse ve NTM deneme verileri olumlu olursa MNKD bu aral\u0131\u011f\u0131n \u00fcst s\u0131n\u0131r\u0131na ula\u015fabilir (<a href=\"https:\/\/stockanalysis.com\/stocks\/mnkd\/forecast\/\">Analist Hedefleri<\/a>).<\/li>\n<li><strong>2026 Tahmini<\/strong>: 6,75-7,25 $<br \/>Afrezza endikasyonlar\u0131n\u0131n geni\u015flemesi ve MNKD-201 Faz 2 ba\u015flat\u0131lmas\u0131 muhtemel b\u00fcy\u00fcmeyi destekleyecektir.<\/li>\n<li><strong>2028 Projeksiyonu<\/strong>: 7,25-7,75 $<br \/>2028\u2019e kadar MNKD-101 ticarile\u015fmesi ve uluslararas\u0131 varl\u0131\u011f\u0131n geni\u015flemesi s\u00fcrd\u00fcr\u00fclebilir b\u00fcy\u00fcmeyi tetikleyecektir.<\/li>\n<li><strong>2030 Uzun Vadeli Hedef<\/strong>: 7,77 $<br \/>Analistler, mevcut b\u00fcy\u00fcme e\u011filimi ve piyasa geni\u015flemesine dayanarak MNKD\u2019nin bu seviyeye ula\u015fabilece\u011fini \u00f6ng\u00f6r\u00fcyor (<a href=\"https:\/\/stockscan.io\/stocks\/MNKD\/forecast\">Uzun Vadeli Tahmin<\/a>).<\/li>\n<\/ul>\n<p><strong>Sonu\u00e7<\/strong>: Uzun vadeli yat\u0131r\u0131mc\u0131lar i\u00e7in <strong>AL<\/strong>. Mevcut fiyat, \u00f6n\u00fcm\u00fczdeki bir\u00e7ok kataliz\u00f6rle cazip bir giri\u015f noktas\u0131 sunuyor.<\/p>\n<h3>\u26a0\ufe0f Temel Riskler ve Pozitif \u0130\u015faretler<\/h3>\n<h4>Dikkate Al\u0131nmas\u0131 Gereken Riskler<\/h4>\n<ul>\n<li><strong>FDA Onay Belirsizli\u011fi<\/strong>: Gecikmeler veya reddedilmeler b\u00fcy\u00fcme yolunu \u00f6nemli \u00f6l\u00e7\u00fcde etkileyebilir<\/li>\n<li><strong>Tedarik Zinciri K\u0131r\u0131lganl\u0131klar\u0131<\/strong>: K\u00fcresel ticaret politikalar\u0131 operasyonel maliyetleri art\u0131rabilir (<a href=\"https:\/\/www.ainvest.com\/news\/mannkind-corporation-faces-global-supply-chain-risks-due-international-trade-policies-2508\/\">Tedarik Zinciri Riskleri<\/a>)<\/li>\n<li><strong>Mali Volatilite<\/strong>: Son bilan\u00e7o, y\u00fck\u00fcml\u00fcl\u00fcklerin cari varl\u0131klar\u0131 ge\u00e7ti\u011fini g\u00f6steriyor<\/li>\n<li><strong>Rekabet Bask\u0131s\u0131<\/strong>: Novo Nordisk ve Eli Lilly gibi b\u00fcy\u00fck oyuncular diyabet alan\u0131nda hakim<\/li>\n<\/ul>\n<h4>2025-2026 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar<\/h4>\n<ul>\n<li><strong>G\u00fc\u00e7l\u00fc Gelir B\u00fcy\u00fcmesi<\/strong>: 2025 2. \u00e7eyrekte %6 Y\u0131ll\u0131k art\u0131\u015f, y\u0131lba\u015f\u0131ndan itibaren %12 y\u00fckseli\u015f<\/li>\n<li><strong>\u00dcr\u00fcn Hatt\u0131 \u0130lerlemesi<\/strong>: NTM Faz 3 denemesinde planlanandan \u00f6nce hasta kayd\u0131<\/li>\n<li><strong>Analist G\u00fcveni<\/strong>: 6 Wall Street analisti &#8220;Al&#8221; notunu koruyor, ortalama hedef fiyat 9,17 $ (+%123 potansiyel)<\/li>\n<li><strong>Stratejik Ortakl\u0131klar<\/strong>: United Therapeutics i\u015fbirli\u011fi rekor royalty gelirleri sa\u011fl\u0131yor<\/li>\n<li><strong>Pazar Geni\u015flemesi<\/strong>: Pediatrik Afrezza ba\u015fvurusu 500M$+ yeni pazar f\u0131rsat\u0131 a\u00e7\u0131yor<\/li>\n<\/ul>\n<h3>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h3>\n<ol>\n<li><strong>K\u00fc\u00e7\u00fck Ba\u015flay\u0131n<\/strong>: Toplam portf\u00f6y\u00fcn\u00fcz\u00fcn %3-5\u2019inden fazlas\u0131n\u0131 temsil etmeyen bir pozisyon b\u00fcy\u00fckl\u00fc\u011f\u00fc ile ba\u015flay\u0131n<\/li>\n<li><strong>Dolar Maliyet Ortalamas\u0131 Kullan\u0131n<\/strong>: M\u00fckemmel giri\u015f zaman\u0131n\u0131 beklemek yerine ayl\u0131k sabit tutarlarda yat\u0131r\u0131m yap\u0131n<\/li>\n<li><strong>Fiyat Uyar\u0131lar\u0131 Kurun<\/strong>: 6 Kas\u0131m kazan\u00e7 tarihi civar\u0131nda potansiyel al\u0131m f\u0131rsatlar\u0131n\u0131 izleyin<\/li>\n<li><strong>\u00c7e\u015fitlendirin<\/strong>: Biyoteknoloji tahsisinizi asla tek bir hisseye koymay\u0131n<\/li>\n<\/ol>\n<p><strong>Deneyimli bir t\u00fcccardan esprili yorum<\/strong>: &#8220;MNKD ticareti, inhalasyon yoluyla ins\u00fclin kullanmak gibidir &#8211; en iyi sonu\u00e7lar i\u00e7in m\u00fckemmel zamanlama gerekir, ama bazen s\u00fcrece g\u00fcvenip o tatl\u0131 emilimi beklemek zorundas\u0131n\u0131z!&#8221;<\/p>\n<h3>\u2705 MannKind Corporation (MNKD) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Ad\u0131m Ad\u0131m<\/h3>\n<table>\n<thead>\n<tr>\n<th>Ad\u0131m<\/th>\n<th>\u0130\u015flem<\/th>\n<th>Neden \u00d6nemli<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Bir Ticaret Platformu Se\u00e7in<\/td>\n<td>NASDAQ listeli hisseleri ve makul komisyon \u00fccretlerini sunmas\u0131na dikkat edin<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Hesab\u0131n\u0131z\u0131 A\u00e7\u0131n ve Fonlay\u0131n<\/td>\n<td>Risk almaya haz\u0131r oldu\u011funuz bir miktarla ba\u015flay\u0131n &#8211; 100 $ bile ba\u015flang\u0131\u00e7 i\u00e7in yeterlidir<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>&#8220;MNKD&#8221; Aramas\u0131 Yap\u0131n<\/td>\n<td>\u015eirket ad\u0131 yerine borsa sembol\u00fcn\u00fc kullan\u0131n<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>Emir T\u00fcr\u00fcn\u00fc Se\u00e7in<\/td>\n<td>Piyasa emirleri yerine limit emirleri kullanarak giri\u015f fiyat\u0131n\u0131z\u0131 kontrol edin<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>\u0130nceleyin ve Onaylay\u0131n<\/td>\n<td>Emir detaylar\u0131n\u0131 iki kez kontrol edin ve i\u015flem \u00f6ncesi \u00fccretleri anlay\u0131n<\/td>\n<\/tr>\n<tr>\n<td>6<\/td>\n<td>Pozisyonunuzu \u0130zleyin<\/td>\n<td>Kazan\u00e7 tarihleri ve \u00f6nemli haberler i\u00e7in uyar\u0131lar kurun<\/td>\n<\/tr>\n<tr>\n<td>7<\/td>\n<td>Vergi Etkilerini D\u00fc\u015f\u00fcn\u00fcn<\/td>\n<td>Avantajl\u0131 vergi muamelesi i\u00e7in tutma s\u00fcresi gereksinimlerini anlay\u0131n<\/td>\n<\/tr>\n<tr>\n<td>8<\/td>\n<td>\u00c7\u0131k\u0131\u015f Stratejinizi Planlay\u0131n<\/td>\n<td>K\u00e2r hedeflerinizi ve zarar durdurma seviyelerinizi \u00f6nceden belirleyin<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h3>\ud83d\udca1 Neden Pocket Option Yeni MNKD Yat\u0131r\u0131mc\u0131lar\u0131 \u0130\u00e7in Uygun?<\/h3>\n<p>MannKind ile yat\u0131r\u0131m yolculu\u011funa ba\u015flamak isteyenler i\u00e7in Pocket Option birka\u00e7 avantaj sunar:<\/p>\n<ul>\n<li><strong>Minimum Para Yat\u0131rma<\/strong>: Sadece 5 $ ile pozisyonunuzu kademeli olarak olu\u015fturmaya ba\u015flayabilirsiniz<\/li>\n<li><strong>H\u0131zl\u0131 Do\u011frulama<\/strong>: Tek bir belge ile KYC i\u015flemini dakikalar i\u00e7inde tamamlay\u0131n<\/li>\n<li><strong>Esnek Para \u00c7ekme<\/strong>: Karlar\u0131n\u0131za y\u00fczlerce \u00f6deme y\u00f6ntemiyle eri\u015fin<\/li>\n<li><strong>E\u011fitim Kaynaklar\u0131<\/strong>: Biyoteknoloji yat\u0131r\u0131m\u0131 hakk\u0131nda kapsaml\u0131 <a href=\"\/blog\">Pocket Option blog<\/a> ile \u00f6\u011frenin<\/li>\n<\/ul>\n<p>Platformun d\u00fc\u015f\u00fck giri\u015f engeli, MannKind hissesiyle stratejileri test etmek i\u00e7in idealdir ve daha b\u00fcy\u00fck yat\u0131r\u0131mlar yapmadan \u00f6nce deneme imkan\u0131 sunar.<\/p>\n<h3>\ud83c\udf0d MannKind 2025\u2019te: \u0130nhalasyon Yoluyla Terap\u00f6tiklerde Devrim<\/h3>\n<p>MannKind Corporation, inhalasyon terap\u00f6tiklerinde yenili\u011fin \u00f6nc\u00fcs\u00fcd\u00fcr. \u00d6zel Technosphere teknolojileri, kuru toz form\u00fclasyonlar\u0131yla derin akci\u011fere h\u0131zl\u0131 emilim sa\u011flar. Bayrak gemisi Afrezza ins\u00fclinlerinin \u00f6tesinde, milyonlarca ki\u015fiyi etkileyen nadir akci\u011fer hastal\u0131klar\u0131 i\u00e7in tedaviler geli\u015ftiriyorlar.<\/p>\n<p>\u015eirketin mevcut piyasa de\u011feri 1,26 milyar $ olup, rekabet\u00e7i biyofarmas\u00f6tik pazarda b\u00fcy\u00fcyen varl\u0131klar\u0131n\u0131 yans\u0131t\u0131yor (<a href=\"https:\/\/stockanalysis.com\/stocks\/mnkd\/\">Piyasa Verileri<\/a>). Son 12 ayl\u0131k gelirleri 301,74 milyon $ ve net geliri 32,80 milyon $ olan \u015firket, yenilik\u00e7i terapileri k\u00e2rl\u0131 \u015fekilde ticarile\u015ftirme yetene\u011fini g\u00f6stermi\u015ftir.<\/p>\n<p><strong>2025 i\u00e7in \u0130lgin\u00e7 Bir Ger\u00e7ek<\/strong>: MannKind\u2019in NTM Faz 3 denemesi (ICoN-1), planlanandan \u00f6nce g\u00fc\u00e7l\u00fc hasta kayd\u0131 ile akci\u011fer hastal\u0131klar\u0131 tarihindeki en h\u0131zl\u0131 hasta toplayan denemelerden biri oldu. Bu beklenmedik h\u0131zlanma, sekt\u00f6r analistlerini \u015fa\u015f\u0131rtt\u0131 ve inhalasyon yoluyla uygulanan klofazimin tedavisine hekimlerin g\u00fc\u00e7l\u00fc ilgisini g\u00f6sterdi.<\/p>\n"},"faq":[{"question":"MannKind hisseleri nas\u0131l sat\u0131n al\u0131n\u0131r?","answer":"Bir arac\u0131 kurumda hesap a\u00e7arak, MNKD sembol\u00fc ile arama yap\u0131p limit veya piyasa emri vererek MannKind hisselerini sat\u0131n alabilirsiniz."},{"question":"MannKind hisselerinin fiyat\u0131 ne kadar?","answer":"24 A\u011fustos 2025 itibar\u0131yla MannKind hisseleri NASDAQ\u2019da 4,11 $ seviyesinden i\u015flem g\u00f6rmektedir."},{"question":"MannKind yat\u0131r\u0131m\u0131nda en \u00f6nemli riskler nelerdir?","answer":"FDA onay belirsizli\u011fi, tedarik zinciri sorunlar\u0131, mali volatilite ve g\u00fc\u00e7l\u00fc rekabet \u00f6nemli riskler aras\u0131ndad\u0131r."},{"question":"MannKind hisseleri i\u00e7in 2025-2030 fiyat tahmini nedir?","answer":"2025 sonunda 6,50-7,00 $, 2030\u2019da ise yakla\u015f\u0131k 7,77 $ seviyeleri hedeflenmektedir."},{"question":"Yeni ba\u015flayanlar MannKind hissesi al\u0131rken nelere dikkat etmeli?","answer":"K\u00fc\u00e7\u00fck pozisyonlarla ba\u015flay\u0131p, dolar maliyet ortalamas\u0131 yapmal\u0131, fiyat uyar\u0131lar\u0131 kurmal\u0131 ve portf\u00f6y\u00fc \u00e7e\u015fitlendirmelidir."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"MannKind hisseleri nas\u0131l sat\u0131n al\u0131n\u0131r?","answer":"Bir arac\u0131 kurumda hesap a\u00e7arak, MNKD sembol\u00fc ile arama yap\u0131p limit veya piyasa emri vererek MannKind hisselerini sat\u0131n alabilirsiniz."},{"question":"MannKind hisselerinin fiyat\u0131 ne kadar?","answer":"24 A\u011fustos 2025 itibar\u0131yla MannKind hisseleri NASDAQ\u2019da 4,11 $ seviyesinden i\u015flem g\u00f6rmektedir."},{"question":"MannKind yat\u0131r\u0131m\u0131nda en \u00f6nemli riskler nelerdir?","answer":"FDA onay belirsizli\u011fi, tedarik zinciri sorunlar\u0131, mali volatilite ve g\u00fc\u00e7l\u00fc rekabet \u00f6nemli riskler aras\u0131ndad\u0131r."},{"question":"MannKind hisseleri i\u00e7in 2025-2030 fiyat tahmini nedir?","answer":"2025 sonunda 6,50-7,00 $, 2030\u2019da ise yakla\u015f\u0131k 7,77 $ seviyeleri hedeflenmektedir."},{"question":"Yeni ba\u015flayanlar MannKind hissesi al\u0131rken nelere dikkat etmeli?","answer":"K\u00fc\u00e7\u00fck pozisyonlarla ba\u015flay\u0131p, dolar maliyet ortalamas\u0131 yapmal\u0131, fiyat uyar\u0131lar\u0131 kurmal\u0131 ve portf\u00f6y\u00fc \u00e7e\u015fitlendirmelidir."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>MannKind Corporation (MNKD) Hisseleri Nas\u0131l Al\u0131n\u0131r - MannKind Corporation (MNKD) Hisse Senedi Yat\u0131r\u0131m\u0131<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-mannkind-corporation\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MannKind Corporation (MNKD) Hisseleri Nas\u0131l Al\u0131n\u0131r - MannKind Corporation (MNKD) Hisse Senedi Yat\u0131r\u0131m\u0131\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-mannkind-corporation\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-24T08:30:07+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-mannkind-corporation\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-mannkind-corporation\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"MannKind Corporation (MNKD) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; MannKind Corporation (MNKD) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"datePublished\":\"2025-08-24T08:30:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-mannkind-corporation\/\"},\"wordCount\":19,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-mannkind-corporation\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals7.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-mannkind-corporation\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-mannkind-corporation\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-mannkind-corporation\/\",\"name\":\"MannKind Corporation (MNKD) Hisseleri Nas\u0131l Al\u0131n\u0131r - MannKind Corporation (MNKD) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-mannkind-corporation\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-mannkind-corporation\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals7.webp\",\"datePublished\":\"2025-08-24T08:30:07+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-mannkind-corporation\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-mannkind-corporation\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-mannkind-corporation\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals7.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals7.webp\",\"width\":1024,\"height\":576},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-mannkind-corporation\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MannKind Corporation (MNKD) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; MannKind Corporation (MNKD) Hisse Senedi Yat\u0131r\u0131m\u0131\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"MannKind Corporation (MNKD) Hisseleri Nas\u0131l Al\u0131n\u0131r - MannKind Corporation (MNKD) Hisse Senedi Yat\u0131r\u0131m\u0131","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-mannkind-corporation\/","og_locale":"tr_TR","og_type":"article","og_title":"MannKind Corporation (MNKD) Hisseleri Nas\u0131l Al\u0131n\u0131r - MannKind Corporation (MNKD) Hisse Senedi Yat\u0131r\u0131m\u0131","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-mannkind-corporation\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-24T08:30:07+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-mannkind-corporation\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-mannkind-corporation\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"MannKind Corporation (MNKD) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; MannKind Corporation (MNKD) Hisse Senedi Yat\u0131r\u0131m\u0131","datePublished":"2025-08-24T08:30:07+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-mannkind-corporation\/"},"wordCount":19,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-mannkind-corporation\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals7.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"tr","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-mannkind-corporation\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-mannkind-corporation\/","url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-mannkind-corporation\/","name":"MannKind Corporation (MNKD) Hisseleri Nas\u0131l Al\u0131n\u0131r - MannKind Corporation (MNKD) Hisse Senedi Yat\u0131r\u0131m\u0131","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-mannkind-corporation\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-mannkind-corporation\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals7.webp","datePublished":"2025-08-24T08:30:07+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-mannkind-corporation\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-mannkind-corporation\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-mannkind-corporation\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals7.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals7.webp","width":1024,"height":576},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-mannkind-corporation\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/tr\/"},{"@type":"ListItem","position":2,"name":"MannKind Corporation (MNKD) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; MannKind Corporation (MNKD) Hisse Senedi Yat\u0131r\u0131m\u0131"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/tr\/#website","url":"https:\/\/pocketoption.com\/blog\/tr\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"tr_TR","wpml_translations":{"vt_VT":{"locale":"vt_VT","id":344547,"slug":"how-to-buy-mannkind-corporation","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu MannKind Corporation (MNKD) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu MannKind Corporation (MNKD)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-mannkind-corporation\/"},"pt_AA":{"locale":"pt_AA","id":344544,"slug":"how-to-buy-mannkind-corporation","post_title":"Como comprar a\u00e7\u00f5es da MannKind Corporation (MNKD) - Investimento em a\u00e7\u00f5es da MannKind Corporation (MNKD)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-mannkind-corporation\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/344546","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/comments?post=344546"}],"version-history":[{"count":1,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/344546\/revisions"}],"predecessor-version":[{"id":344549,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/344546\/revisions\/344549"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media\/334045"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media?parent=344546"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/categories?post=344546"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/tags?post=344546"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}